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Background: Cancers have a multifactorial etiology a part of which is genetic. Recent data indicate that expression
of the tight junction claudin proteins is involved in the etiology and progression of cancer.
Methods: To explore the correlations of the tight junction proteins claudin-2,-6, and −11 in the pathogenesis and
clinical behavior of gastric cancer, 40 gastric cancer tissues and 28 samples of non-neoplastic tissues adjacent to the
tumors were examined for expression of claudin-2,-6, and −11 by streptavidin-perosidase immunohistochemical
staining method.
Results: The positive expression rates of claudin-2 in gastric cancer tissues and adjacent tissues were 25% and 68%
respectively (P < 0.001). The positive expression rates of claudin-6 in gastric cancer tissues and adjacent tissues were
55% and 79% respectively (P = 0.045 < 0.05). In contrast, the positive expression rates of claudin-11 in gastric cancer
tissues and gastric cancer adjacent tissues were 80% and 46% (P = 0.004 < 0.01). Thus in our study, the expression of
claudin-2, and claudin-6 was down regulated in gastric cancer tissue while the expression of claudin-11 was up
regulated. Correlations between claudin expression and clinical behavior were not observed.
Conclusion: Our study provides the first evidence that claudin-2,-6, and −11 protein expression varies between
human gastric cancers and adjacent non-neoplastic tissues.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5470513569630744
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The progression of cancer is accompanied by multiple
genetic and epigenetic alterations that have potential as
markers for early diagnosis, treatment, and prevention
[1]. Gastric cancer has become the second leading cause
of cancer mortality worldwide accounting for almost
10% of newly diagnosed cancers [2]. Generally, early
diagnosis of gastric cancer is difficult because patients
tend to be asymptomatic until the tumors have reached
an aggressive stage [3]. Accordingly, identification of* Correspondence: quancs@jlu.edu.cn
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reproduction in any medium, provided the orspecific early genetic markers of gastric tumorigenesis
becomes significant. It has been reported that the endo-
thelial lipase protein is a promising urinary biomarker
for diagnosis of gastric cancer and is potentially appli-
cable to general screening for cancer with high sensiti-
vity and specificity [4]. Decreased Plakophilins (PKP2
and PKP3) may be early prognostic markers and loss of
PKP3 expression during gastric carcinoma progression
may indicate an invasive phenotype [5]. Moreover, the
up regulation of differentiated embryonic chondrocyte-
expressed gene 1 may play an important role in hypoxia
regulation and cell proliferation in gastric cancer [6].
The detection of Ezrin expression can be used as a
marker for early diagnosis and prognosis of gastric
adenocarcinoma [7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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endothelial cells that participate in the formation of
intercellular junctional complexes. Tight junctions con-
tribute to epithelial cell permeability, maintenance of cell
polarity, and barrier function [8,9]. The claudin protein
family is involved in formation of tight junctions (TJs),
and consists of approximately 27 members, which are
expressed with a tissue-specific distribution [10]. Malig-
nant cells frequently display structural and functional
disruption of the tight junctions [11]. Recently, the ab-
normal expression of members of the claudin protein
family has been reported to participate in tumorigenesis
[12]. For instance, claudin-3 and claudin-4 have been
found to be regularly elevated in ovarian, breast, prostate
and pancreatic tumors [13]. This observation suggests
that alterations in claudin expression may occur as a
common phenomenon related to human tumorigenesis
and tumor progression. Moreover, claudin-4 has been
reported to be highly unregulated in gastric cancer, with
an association between the up-regulation of claudin-4
and lymph node metastasis [14]. Claudin-6 protein is
significantly down-regulated in breast invasive ductal
carcinomas and is an important correlate with lymphatic
metastasis [15]. Together such observations suggest that
claudin protein expression may be related to the survival
and invasion of cancer cells and may have significant
clinical relevance. However, to our knowledge, the exact
expression patterns of the claudin protein family in
gastric cancer have not been defined.
It has been reported that claudin-18 expression has been
shown to have prognostic value in gastric cancer [16] and
claudin-3,-4 and-7 expression are similarly elevated in gas-
tric cancer [17]. Resnick et al. have determined that
claudin-1,-3, and-4 and ZO-1 are strongly expressed in
most gastric intestinal-type adenocarcinomas [18]. Strong
expression of claudin-5 was associated with higher
cell proliferation and apoptosis in gastric cancer [19].
In summary, in gastric cancer, claudin protein expres-
sion has been demonstrated to be of great importance
and a relevant area for further study. Thus, the ob-
jective of this study was to examine the expression of
claudin-2,-6, and −11 in gastric carcinoma and adja-
cent tissue which have been less well studied. We
used immunohistochemical staining, and correlated the
expression of these proteins with tumor differentiation
and stage. One goal was to explore the feasibility of using
claudin-2, -6, and −11 as potential prognostic markers.
Materials and methods
Patients
Paraffin blocks from forty specimens of gastric cancer and
twenty-eight specimens ofhistologically normal tissue
adjacent to the neoplasms were collected from patients
being treated at the Second Hospital of Jilin Universityduring the period between March 2011 and June 2011.
The patients 'medical records were reviewed to determine
their age and gender. Sections of the primary tumor were
analyzed to identify the histological grade, and the pre-
sence or absence of regional lymph node metastasis.
There were 31 men and 9 women with average age of
63 years. Eleven tumors had well differentiated histological
appearance, another twenty-seven tumors were of mode-
rately and poor differentiated. Whereas the remaining 2
cases were mucinous cyst-adenocarcinoma. For the use of
these clinical materials for research purposes, prior pa-
tient’s consent and approval from the Institute Research
Ethics Committee was obtained. All the cancer cases were
classified and graded according to the International Union
Against Cancer (UICC) staging system for gastric cancer.
Materials
Rabbit antihuman claudin-2 antibody (BS1066), rabbit
antihuman claudin-6 antibody (BS3107), rabbit anti-
human claudin-11 antibody (BS1056) were purchased
from Bioworld Technology (USA) and an streptavidin-
perosidase immunohistochemistry reagent kit were
purchased from Maixin Biology (Fujian, China).
Immunohistochemistry
The sections were dewaxed by heating at 55°C for
30 min and subjected to two 15 min washes with xylene.
Then, the sections were rehydrated by a series of 5 min
washes in ethanol. The sections were placed into an
enamel cylinder containing 10 mmol/L sodium citrate
(pH 6.0), heated by gas cooker at 95°C for 5 min for
antigen unmasking, and then were treated with 3%
hydrogen peroxide for 30 min to inactivate endogenous
peroxidase activity. After being incubated with fetal
bovine serum for 30 min and sections were then
incubated at 4°C overnight with rabbit anti-human
claudin-2 antibody, rabbit antihuman claudin-6 anti-
body, or rabbit antihuman claudin-11 antibody diluted
1:400, 1:300, and 1:400 respectively. The sections were
then washed with PBS and incubated for 30 min with
biotinylated goat anti-rabbit secondary antibody at 37°C.
The substrate, 3′3-diaminobenzidine tetrachloride, dis-
solved in steamed water, was added to visualize the
positive expression. Negative control sections were im-
munostained as described above, but incubated with
PBS instead of a primary antibody.
Criteria for the positive claudin-2,-6 and-11 expression in
tissue
The cells positively expressing claudin-2, -6, and-11 were
identified by brown staining of their cytoplasm or cell
membrane after reaction with claudin-2, -6, or −11 anti-
body. The claudin-2,-6,-11 positive tissues were quanti-
fied based on the percentage of positive cells which were
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counting was repeated in five randomly-selected micro-
scopic fields at × 400 magnification. The claudin-2 nega-
tive groups were defined as a field with level less than
20% (of the tumor cells); positive groups had more than
20% positive cells. The claudin-6 negative group had less
than 15% stained cells and the positive group more than
15%. The claudin-11 negative group contained less than
30% positive cells and the positive group, more greater
than 30%.
Statistical analysis
The Chi-square test/Chi-Square Goodness-of-Fit Test
was used to determine the prognostic significance
value for disease progression of each factor alone,
using a P-value < 0.05 for statistically significant asso-
ciations. All the data were analyzed using SPSS 12.0
statistical software.
Results
Population and tumor characteristics
The clinicopathological characteristics of the patients
are summarized in Table 1. Negative nodes were found
in 15 cases; a total of 25 patients had positive metastatic
nodes.
The expression of claudin-2 and claudin-6 was reduced in
gastric cancer
In our study, claudin-2 expression was evaluated in the
cytoplasm or membranes of 40 gastric cancers tissues
and 28 specimens containing gastric tissue adjacent to
the carcinoma. Positive expression of claudin-2 protein
was found in 25.0% (10/40) of gastric carcinoma tissuesTable 1 Expression of CLDN2, CLDN6, CLDN11 and clinicopat
Item n CLDN2(+) CLDN2(-) P n
Gastric cancer tissue 40 10 30 <0.001 40
Adjacent tissue 28 19 9 28
Gender
Male 31 9 22 0.404* 31
Female 9 1 8 9
Age (year)
≤60 17 4 13 1.000* 17
>60 23 6 17 23
Histological grade
Well -differentiated 11 3 8 1.000* 11
Moderately and poor differentiated 27 7 20 27
Lymph node metastasis
+ 25 7 18 0.715* 25
- 15 3 12 15
* No statistical significance.and in 67.8% (19/28) of adjacent tissues (Table 1). The
expression of claudin-2 in gastric cancer tissues was sig-
nificantly lower than in adjacent tissues (The Chi-
square test/Chi-Square Goodness-of-Fit Test, P < 0.001)
(Figure 1A,B). As shown in Table 1 the expression of
claudin-2 was not correlated with age (P =1.000), sex
(P =0.404), histological grade (P = 1.000), or lymph node
metastasis (P = 0.715).
Positive expression of claudin-6 protein was found in
55.0% (22/40) of gastric cancer tissues and in 78.6%
(22/28) of adjacent tissues (Table 1). The expression
rate of claudin-6 in gastric cancer tissues was lower
than the rate in adjacent tissues (The Chi-square test/
Chi-Square Goodness-of-Fit Test, P =0.045 < 0.05)
(Figure 1C,D). As shown in Table 1, the expression of
claudin-6 was also not correlated with age (P =0.385),
sex (P =0. 705), histological grade (P = 1.000), or lymph
node metastasis (P = 0.870).
The expression of claudin-11 was increased in gastric
cancer
The cytoplasmic staining of claudin-11 was strong in
gastric cancer tissues and weak in adjacent tissues.
Claudin-11 was expressed in 80.0% (32/40) of gastric
cancer tissues. Cells were positive for claudin-11 in
46.4% (13/28) of tissues adjacent to the cancer. We con-
clude that claudin-11 expression is significantly higher
(Figure 1E,F) in gastric cancer samples than in histolo-
gically normal gastric tissue. (The Chi-square test/Chi-
Square Goodness-of-Fit Test, x2 = 8.293, P < 0.01). The
expression of claudin-11 was not correlated with age
(P =0.677), sex (P =0. 645), histological grade (P = 1.000),
or lymph node metastasis (P = 0.224).hological characteristics in gastric cancer patients
CLDN6(+) CLDN6(-) P n CLDN11(+) CLDN11(-) P
22 18 0.045 40 32 8 0.004
22 6 28 13 15
18 13 0.705* 31 26 5 0.645*
4 5 9 7 2
8 9 0.385 17 15 2 0.677*
14 9 23 18 5
6 5 1.000* 11 9 2 1.000*
15 12 27 21 6
14 11 0.870 25 19 6 0.224*
8 7 15 14 1
Figure 1 Immunohistochemical demonstration of claudin protein expression in human gastric cancer and adjacent tissue. Claudins
were expressed in the cell cytoplasm and membrane. (A), claudin-2 was highly expressed in epithelial cells adjacent to gastric cancer but was
expressed at low levels in cancer tissue itself (B). (C), the strong expression of claudin-6 in tissue adjacent to human gastric cancer compared to
low expression of claudin-6 in human gastric cancer tissue (D). (E), low claudin-11 expression was detected in tissue adjacent to human gastric
cancer compared with high claudin-11 expression in human gastric cancer tissue (F) (400×).
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in gastric cancer
We investigated the correlation between claudin-2,
claudin-6 and claudin-11 expression using The Chi-
square test/Chi-Square Goodness-of-Fit Test. Although
we did not find a correlation between claudin-11 and
claudin-2 (The Chi-square test/Chi-Square Goodness-
of-Fit Test, φ = 0.168, P = 0.405) or with claudin-6 (The
Chi-square test/Chi-Square Goodness-of-Fit Test, φ =
0.176, P = 0.430), we found that the expression of
claudin-2 was positively correlated with the expression of
claudin-6 (The Chi-square test/Chi-Square Goodness-of-Fit
Test, φ =0.376, P = 0.028). The detailed results of the
analysis are described in Tables 2 and 3.Table 2 Correlation between the expression of claudin-6 and
Item CLDN2(+) CLDN2(-) φ* P
CLDN6(+) 8 11 0.376 0.02
CLDN6(-) 2 19
*φ Phi coefficient.Discussion
Currently, the disruption of claudins expression is re-
garded as one of the mechanisms responsible for loss of
cell adhesion, altered polarity, poor differentiation and
increased invasive potential of neoplastic cells [20-23].
Although the normal ratio of claudins protein has a role
in maintaining the structure and function of tight junc-
tions in epithelial cells [24], the mechanisms by which
claudin expression and destruction of tight junctions
induce tumor formation and the effect of these changes
on tumor progression have not been studied in detail. It
has been postulated that both abnormal up-regulation
and down-regulation of claudin proteins would cause the
structural and functional disruption of tight junctions, forclaudin-2
CLDN11(+) CLDN11(-) φ* P
8* 19 3 0.176 0.430
13 5
Table 3 Correlation between the expression of claudin-2
and claudin-11
Item CLDN11(+) CLDN11(-) φ* P
CLDN2(+) 10 1 0.168 0.405
CLDN2(-) 22 7
*φ Phi coefficient.
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of intercellular space, and weakening of tight junction
cohesion [25]. In addition, the alteration of claudins pro-
tein expression can regulate cellular proliferation, differen-
tiation, survival, and apoptosis through a series of signal
transduction pathways, thus, playing an important role in
tumorigenesis and tumor metastasis [26,27]. Claudin-4
has been shown to activate MMP-2 and claudin-4 expres-
sion has been significantly associated with MMP-9 expres-
sion, indicating that claudin-mediated increased cancer
cell invasion result from activation of MMP proteins [28].
Phosphorylation of claudin-3 by cAMP-dependent protein
kinase and claudin-4 by Ephrin Type-A Receptor 2 can
modulate cell-to-cell contact [29,30]. Claudin-1 is involved
in the β-catenin- T-cell Factor/ Lymphoid Enhancing
Factor signaling pathway, and increased expression of
claudin-1 may be a component of colorectal tumorige-
nesis [31]. It has been reported that Claudin-7 unlike
other claudins, has both structural and regulatory func-
tions and may be related to cell differentiation [32]. Al-
teration of claudin expression may affect permeability at
tight junction, possibly increasing the diffusion of nut-
rients and other extracellular growth factors to promote
cancer cell growth, survival and motility in gastric cancer
[33]. In brief, claudin proteins may participate in regula-
tion of cell proliferation, differentiation and apoptosis
directly and indirectly [34].
Recently, claudin-2 has been reported selective up-
regulated in colorectal cancer and may be useful as
tumor markers and targets for the treatment of colo-
rectal cancer [35]. Nevertheless, claudin-2 protein ex-
pression was significantly down-regulated in tumors
compared with corresponding normal breast tissue.
Down-regulation of claudin-2 was significantly asso-
ciated with lymph node metastasis in breast carcinomas
by Western blot analysis, and with high clinical stage
by immunohistochemistry [36]. Similarly, claudin-2
were selective down-regulated in gastric cancer com-
pared with corresponding cancer adjacent tissues in
our present data. However, the association between
claudin-2 protein expression with high clinical stage
and lymph node metastasis has not been observed.
We cloned putative mammary cancer suppressor
(mes) gene claudin-6 in mammary epithelial cells puri-
fied from Cop rat that extremely resistant to mammary
cancer reduced by a variety of carcinogen. We have alsoreported that up-regulation of claudin-6 may induce
apoptosis and decrease clone formation, invasiveness
and migration of MCF-7 in vitro [37]. Epigenetic silen-
cing of claudin-6 promoted anchorage-independent
growth, cellular invasiveness and transendothelial mi-
gration of breast carcinoma cells, accompanied by an in-
crease in matrix metalloproteinase activity [38]. It is
reported that apoptosis signal-regulating kinase 1 is as-
sociated with the effect of claudin-6 in breast cancer
[39]. Recent gene expression microarray analyses have in-
dicated that claudin-6 is specifically expressed in atypical
teratoid rhomboid tumors (AT/RTs), suggesting a role as a
positive diagnostic marker of AT/RTs [40]. On the con-
trary, in the present study we found that claudin-6 protein
wan expressed at low levels in gastric carcinoma tissues
but highly expressed in histologically normal adjacent
tissues.
Claudin-11, an oligodendrocyte protein, has been
shown to interact with α1-integrin and to regulate the
proliferation and migration of oligodendrocytes in cul-
ture [41]. Loss of claudin-11 may be considered to be
putative indicators of recurrence and more aggressive
behavior of meningiomas [42]. Accordingly, the over-
expression of claudin-11 would decreases the invasive
potential of bladder cancer cells in vitro [43]. However,
in our present work the cytoplasmic staining of claudin-
11 was strong in gastric cancer tissues and weak in adja-
cent tissues, reveals that claudin-11 may be a positive
diagnostic marker in gastric cancer which was different
with claudin-2 and claudin-6. In addition, recent data re-
veals that claudin-16 and claudin-19 interact and form a
tight junction complex generated cation selectivity of the
TJ in a synergistic manner [44].
Our present data observes that claudin-2 and claudin-
6 were both down-regulated and may be concurrently
expressed in gastric cancer, reveals that claudin-2 and
claudin-6 may act as synergistic tumor suppressors in
gastric cancer. Nevertheless, the correlations between
claudin-11 expression with claudin-2 and claudin-6
expression have not been observed.Conclusion
The present work infers that the expression altered of
claudin-2, claudin-6, and claudin-11 between human
gastric cancers and adjacent non-neoplastic tissues and
does not correlate with their clinical behavior. In
addition, claudin-2 and claudin-6 may be concurrently
expressed in gastric cancer. However, the specific me-
chanism responsible for these observations needs to be
addressed in the future.Competing interests
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